22nd Century Group (XXII) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
26 Dec, 2025Executive summary
Completed a major restructuring and turnaround in 2024, shifting focus to a pure-play tobacco company and divesting non-core hemp cannabis operations.
Net revenues for Q4 2024 were $4.0M, down from $5.9M in Q3; full year 2024 revenues were $24.4M, down 24% year-over-year.
Operating loss increased to $4.1M in Q4 and $14.0M for the year, reflecting ongoing turnaround efforts.
Launched new VLN branding and announced first partner brand with Smoker Friendly, with shipments expected in Q2 2025.
Positioned for growth in 2025 with a focus on the VLN reduced-nicotine product and contract manufacturing (CMO) business.
Financial highlights
Q4 2024 net revenue was $4.0M, down from $5.9M in Q3 2024, due to lower volumes from repricing and contract transitions.
Gross margin loss of $1.3M in Q4 2024, compared to $588,000 in the prior period; full year gross loss was $2.4M.
Operating expenses for Q4 2024 were $2.8M, flat sequentially.
Net working capital improved to $1.6M from a deficit of $8.8M year-over-year.
Ended 2024 with net total debt of $3.3M, down from $13.3M at end of 2023.
Outlook and guidance
Expecting volume and revenue growth in Q1 and Q2 2025 as repriced CMO contracts ramp up.
Rebranded VLN and partner VLN products to begin shipping in Q2 2025, with gradual market expansion.
Targeting break-even EBITDA in Q4 2025 and first-time profitability in company history.
Company expects to benefit from FDA's proposed nicotine standards, with VLN as the only compliant product.
Latest events from 22nd Century Group
- Revenue grew, losses narrowed, but going concern risk persists as VLN rebranding continues.XXII
Q2 20241 Feb 2026 - Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 2024 revenue dropped 24.5% with ongoing losses, but net debt and cost structure improved.XXII
Q3 202414 Jan 2026 - Key votes include a reverse split, preferred stock, warrant changes, and a new offering.XXII
Proxy Filing30 Dec 2025 - Relaunching low-nicotine brands, expanding retail reach, and targeting profitability by Q4 2025.XXII
Emerging Growth Conference26 Dec 2025 - Special meeting seeks approval for reverse split, anti-dilution terms, and new capital offering.XXII
Proxy Filing19 Dec 2025 - Resale of 1.4M shares enables debt settlement for a tobacco innovator with FDA-authorized VLN products.XXII
Registration Filing16 Dec 2025 - Registering 104,124 shares for resale, with no proceeds to the company and ongoing financial risks.XXII
Registration Filing16 Dec 2025 - Registering 93.6M shares for resale; proceeds only from warrant exercises; faces losses and regulatory risks.XXII
Registration Filing16 Dec 2025